Alnylam Pharmaceuticals (ALNY) News Today $461.37 +0.23 (+0.05%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALNY Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Raised by Swedbank ABSeptember 16 at 4:03 AM | marketbeat.comAG2R LA Mondiale Gestion D Actifs Buys Shares of 5,825 Alnylam Pharmaceuticals, Inc. $ALNYSeptember 16 at 4:02 AM | marketbeat.comStrs Ohio Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNYSeptember 16 at 3:37 AM | marketbeat.comAscent Group LLC Invests $202,000 in Alnylam Pharmaceuticals, Inc. $ALNYSeptember 15 at 3:59 AM | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Decreases Stock Position in Alnylam Pharmaceuticals, Inc. $ALNYSeptember 15 at 3:30 AM | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $421.28 Average Price Target from BrokeragesSeptember 15 at 2:48 AM | americanbankingnews.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Lowers Stock Position in Alnylam Pharmaceuticals, Inc. $ALNYSeptember 14 at 4:18 AM | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 14 at 2:44 AM | marketbeat.comColleen Reitan Sells 18,000 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) StockSeptember 13 at 5:43 PM | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $515.05September 13 at 9:59 AM | marketbeat.comWill Positive HELIOS-B Data and $575 Million Offering Transform Alnylam’s (ALNY) RNAi Therapy Narrative?September 13 at 9:47 AM | finance.yahoo.comAlnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Plato Investment Management LtdSeptember 13 at 4:53 AM | marketbeat.comEvercore ISI Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $515.05September 13 at 3:37 AM | americanbankingnews.comBridgeBio Says Pfizer, Alnylam Aren’t Playing Fair in Blockbuster RaceSeptember 12, 2025 | msn.comInsider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) Director Sells 18,000 Shares of StockSeptember 12, 2025 | insidertrades.comWoodline Partners LP Takes $42.25 Million Position in Alnylam Pharmaceuticals, Inc. $ALNYSeptember 12, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 52-Week High - What's Next?September 11, 2025 | marketbeat.comSCS Capital Management LLC Purchases New Holdings in Alnylam Pharmaceuticals, Inc. $ALNYSeptember 11, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comAlnylam Pharmaceuticals, Inc. $ALNY Stock Position Lowered by Voleon Capital Management LPSeptember 10, 2025 | marketbeat.com998 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by EP Wealth Advisors LLCSeptember 10, 2025 | marketbeat.comAlnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior NotesSeptember 9, 2025 | businesswire.comAlnylam announces proposed offering of $500M convertible senior notesSeptember 9, 2025 | msn.comHere's How Much $1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth TodaySeptember 9, 2025 | benzinga.comAlnylam (ALNY) should rally into $479-$494 before correction startSeptember 9, 2025 | fxstreet.comAlnylam Announces Proposed Offering of $500 Million Convertible Senior NotesSeptember 9, 2025 | finance.yahoo.comParkman Healthcare Partners LLC Raises Position in Alnylam Pharmaceuticals, Inc. $ALNYSeptember 8, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Takes Position in Alnylam Pharmaceuticals, Inc. $ALNYSeptember 8, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Vident Advisory LLCSeptember 8, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Rating Lowered to Buy at Wall Street ZenSeptember 8, 2025 | americanbankingnews.comAlnylam’s TRITON-CM Study: A Potential Breakthrough in Cardiomyopathy TreatmentSeptember 7, 2025 | msn.comWhat is HC Wainwright's Estimate for ALNY Q3 Earnings?September 7, 2025 | marketbeat.comFocus Partners Advisor Solutions LLC Buys 1,862 Shares of Alnylam Pharmaceuticals, Inc. $ALNYSeptember 7, 2025 | marketbeat.comHC Wainwright Issues Optimistic Outlook for ALNY EarningsSeptember 7, 2025 | americanbankingnews.comEFG Asset Management North America Corp. Sells 1,955 Shares of Alnylam Pharmaceuticals, Inc. $ALNYSeptember 6, 2025 | marketbeat.comEventide Asset Management LLC Has $44.94 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNYSeptember 6, 2025 | marketbeat.comCinctive Capital Management LP Has $6.71 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNYSeptember 6, 2025 | marketbeat.comBridger Management LLC Cuts Position in Alnylam Pharmaceuticals, Inc. $ALNYSeptember 5, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by AQR Capital Management LLCSeptember 5, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Buys 189,128 Shares of Alnylam Pharmaceuticals, Inc. $ALNYSeptember 5, 2025 | marketbeat.comAlnylam Pharma (ALNY) Receives a Buy from TD CowenSeptember 4, 2025 | theglobeandmail.comAlnylam Pharma (ALNY) Gets a Buy from Piper SandlerSeptember 4, 2025 | theglobeandmail.comAre Options Traders Betting on a Big Move in Alnylam Pharmaceuticals Stock?September 4, 2025 | msn.comAlnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at HC WainwrightSeptember 4, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given New $583.00 Price Target at CitigroupSeptember 4, 2025 | marketbeat.comPalo Alto Investors LP Reduces Position in Alnylam Pharmaceuticals, Inc. $ALNYSeptember 4, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Reduces Stock Position in Alnylam Pharmaceuticals, Inc. $ALNYSeptember 4, 2025 | marketbeat.comCanada Pension Plan Investment Board Has $16.35 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNYSeptember 4, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks TranscriptSeptember 3, 2025 | seekingalpha.comInnovationRx: Inside The Crisis At The CDCSeptember 3, 2025 | forbes.com Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALNY Media Mentions By Week ALNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALNY News Sentiment▼1.050.92▲Average Medical News Sentiment ALNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALNY Articles This Week▼2921▲ALNY Articles Average Week Get the Latest News and Ratings for ALNY and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Amgen News Gilead Sciences News Vertex Pharmaceuticals News Regeneron Pharmaceuticals News Biogen News United Therapeutics News Incyte News Neurocrine Biosciences News BioMarin Pharmaceutical News Exact Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALNY) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
